{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:02:48Z","timestamp":1762351368713,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.farma.2023.09.008","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:37:30Z","timestamp":1697297850000},"page":"T9-T15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"48","author":[{"given":"Francisco Javier","family":"Salmer\u00f3n-Navas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester Mar\u00eda","family":"Barreiro-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"F\u00e9nix-Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"800","key":"10.1016\/j.farma.2023.09.008_bb0005","first-page":"52","article-title":"Leucemia linf\u00e1tica cr\u00f3nica B. Diagnostico, pron\u00f3stico y tratamiento","volume":"100","author":"Garcia-Martin","year":"2017","journal-title":"Actual. Med."},{"key":"10.1016\/j.farma.2023.09.008_bb0010","first-page":"29","article-title":"Leucemia linfoc\u00edtica cr\u00f3nica. Lux","author":"Arias-Segura","year":"2013","journal-title":"Medica."},{"author":"Global LLC","key":"10.1016\/j.farma.2023.09.008_bb0015"},{"year":"2022","series-title":"Estad\u00edsticas importantes sobre la leucemia linfoc\u00edtica cr\u00f3nica [monograf\u00eda en Internet]","author":"Sociedad Americana contra el C\u00e1ncer","key":"10.1016\/j.farma.2023.09.008_bb0020"},{"author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.farma.2023.09.008_bb0025"},{"author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.farma.2023.09.008_bb0030"},{"issue":"11","key":"10.1016\/j.farma.2023.09.008_bb0035","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"issue":"10232","key":"10.1016\/j.farma.2023.09.008_bb0040","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet."},{"issue":"8","key":"10.1016\/j.farma.2023.09.008_bb0045","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.farma.2023.09.008_bb0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.medcli.2013.11.033","article-title":"Evaluaci\u00f3n y posicionamiento de medicamentos como alternativas terap\u00e9uticas equivalentes [Assessment and positioning of drugs as equivalent therapeutic alternatives]","volume":"143","author":"Alegre Del Rey","year":"2014","journal-title":"Med Clin (Barc)"},{"author":"Primo J. Calculadoras","key":"10.1016\/j.farma.2023.09.008_bb0055"},{"issue":"6","key":"10.1016\/j.farma.2023.09.008_bb0060","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol."},{"year":"2009","series-title":"Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis [monograf\u00eda en Internet]","author":"Wells","key":"10.1016\/j.farma.2023.09.008_bb0065"},{"issue":"10","key":"10.1016\/j.farma.2023.09.008_bb0070","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.farma.2023.09.008_bb0075","series-title":"Especializaci\u00f3n en C\u00e1ncer de Mama para Farmacia Hospitalaria","article-title":"Asignatura 4: Seguimiento de Pacientes con C\u00e1ncer de Mama Metast\u00e1sico, Medici\u00f3n de resultados en salud y calidad de vida. Pros y datos de pr\u00e1ctica cl\u00ednica","author":"Espinosa Bosch","year":"2022"},{"issue":"9265","key":"10.1016\/j.farma.2023.09.008_bb0080","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(00)04522-0","article-title":"Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk\u2013benefit contours","volume":"357","author":"Shakespeare","year":"2001","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.farma.2023.09.008_bb0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am J Hematol."},{"author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.farma.2023.09.008_bb0090"},{"issue":"4","key":"10.1016\/j.farma.2023.09.008_bb0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.farma.2023.09.008_bb0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clml.2020.10.012","article-title":"Comparison between venetoclax-based and bruton tyrosine kinase inhibitor-based therapy as upfront treatment of chronic lymphocytic leukemia (CLL): a systematic review and network meta-analysis","volume":"21","author":"Molica","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.farma.2023.09.008_bb0105","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.clinthera.2020.08.017","article-title":"Comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia: a systematic review and network meta-analysis","volume":"42","author":"Davids","year":"2020","journal-title":"Clin Ther."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323008899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323008899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:43Z","timestamp":1761106663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634323008899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1130634323008899"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2023.09.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.07.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}